NeuroSigma, US Veterans Administration (VA) enter into cooperative research and development agreement

Published 16 October 2014

NeuroSigma a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Veterans Affairs (VA) for a clinical trial to evaluate the benefits of non-invasive, external Trigeminal Nerve Stimulation (eTNS) for patients with traumatic brain injury (TBI) in a Phase I clinical trial.

Jean-Philippe Langevin, M.D., an expert in neurotrauma and a neurosurgeon at the Veterans Affairs Greater Los Angeles (VAGLA) medical center, will lead the study as Principal Investigator. The project will enroll U.S. military veterans with TBI in an eight-week treatment protocol, and will examine change in cognitive function and regional brain activity as people receive nightly eTNS treatment at home.

TBI is a condition that arises after mechanical injury to the brain. According to the Centers for Disease Control and Prevention, an estimated 5.3 million Americans currently live with TBI-related disability, with an annual total cost in 2010 estimated at $76.5 billion, including $11.5 billion in direct medical costs and $64.8 billion in indirect costs including lost wages, lost productivity, and nonmedical expenditures.

The Department of Defense has reported approximately 200,000 cases of TBI in troops between 2000 and June 2010. While many individuals recover fully, approximately 15 to 34 percent of individuals with mild or moderate TBI have persistent symptoms that may interfere with their return to work or school, including difficulties with memory, decision making, attention, movement, and emotional functioning. These issues not only impact the injured individuals, but also can have lasting effects on their families and communities.

"We are excited to be working with Dr. Langevin and his colleagues on this important project. There is an acute need for more non-invasive TBI treatment options, not only for our veterans returning from overseas combat operations but also for the millions of Americans involved in motor vehicle accidents, falls, and sports-related concussions," said Lodwrick M. Cook, Chairman of NeuroSigma.

"Neuroimaging data from PET scans suggest that eTNS can influence the activity of certain brain areas associated with the cognitive functions that are disrupted in TBI. This effect may be able to help these individuals overcome their impairments and the purpose of this study is to gather evidence related to this hypothesis." added Ian A. Cook, M.D., NeuroSigma's Chief Medical Officer and Senior Vice President.

"We owe it to our veterans to evaluate whether eTNS can help with TBI and are delighted to support this important Phase I clinical trial by supplying Monarch eTNS systems. We are excited to be adding TBI to our pipeline of therapies under development," said Leon Ekchian, Ph.D., NeuroSigma's President and CEO.

In August 2012, NeuroSigma received CE Mark approval to market NeuroSigma's first trigeminal nerve stimulation (TNS) product, the Monarch eTNS System, in the European Union, for the adjunctive treatment of epilepsy and major depressive disorder (MDD) for adults and children nine years and older.

In addition, the Monarch eTNS System also received a Class II medical device license from Health Canada in April of 2013 allowing NeuroSigma to market the system for treatment of drug-resistant epilepsy (DRE) and MDD for adults and children nine years and older.

Read the rest here:
NeuroSigma, US Veterans Administration (VA) enter into cooperative research and development agreement